A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

This study has been completed.

Study NCT00528333 Information provided by Seattle Genetics, Inc.

First Received: September 10, 2007 Last Updated: October 7, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	August 2010
Primary Completion Date:	August 2010 (Final data collection date for primary outcome measure)
Certification - "Seeking Initial Approval":	Submission Date: October 7, 2011